Braco-19
Modify Date: 2026-07-01 08:32:28
Braco-19 structure
|
Common Name | Braco-19 | ||
|---|---|---|---|---|
| CAS Number | 351351-75-2 | Molecular Weight | 593.76200 | |
| Density | 1.275g/cm3 | Boiling Point | 854.95ºC at 760 mmHg | |
| Molecular Formula | C35H43N7O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 470.857ºC | |
Use of Braco-19Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor[1][2]. |
| Name | N-[9-[4-(dimethylamino)anilino]-6-(3-pyrrolidin-1-ylpropanoylamino)acridin-3-yl]-3-pyrrolidin-1-ylpropanamide |
|---|---|
| Synonym | More Synonyms |
| Description | Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: telomerase/telomere[1] |
| In Vitro | Braco-19, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication[2]. BRACO-19 (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC100 is 5 μM[1]. BRACO-19 (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses[1]. BRACO-19 (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells[2]. BRACO-19 (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner[2]. Cell Viability Assay[1] Cell Line: HEK 293 cells Concentration: 20 μM; 40 μM Incubation Time: 24 hours Result: Displayed low cytotoxicity and decreased the eGFP fluorescence. |
| In Vivo | BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts[1]. BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors)[1]. Animal Model: Established UXF1138LX Xenografts in nude mice[1] Dosage: 2 mg/kg Administration: Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments Result: Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control. |
| References |
| Density | 1.275g/cm3 |
|---|---|
| Boiling Point | 854.95ºC at 760 mmHg |
| Molecular Formula | C35H43N7O2 |
| Molecular Weight | 593.76200 |
| Flash Point | 470.857ºC |
| Exact Mass | 593.34800 |
| PSA | 103.05000 |
| LogP | 6.64310 |
| Index of Refraction | 1.708 |
| InChIKey | RKPYSYRMIXRZJT-UHFFFAOYSA-N |
| SMILES | CN(C)c1ccc(Nc2c3ccc(NC(=O)CCN4CCCC4)cc3nc3cc(NC(=O)CCN4CCCC4)ccc23)cc1 |
| Hazard Codes | Xi |
|---|
![N-[9-chloro-6-(3-pyrrolidin-1-yl-propionylamino)-acridin-3-yl]-3-pyrrolidin-1-yl-propionoamide structure](https://image.chemsrc.com/caspic/044/351351-79-6.png)
![3,6-bis-[3-pyrrolidinopropionamide]-9-acridone structure](https://image.chemsrc.com/caspic/082/351351-78-5.png)
![3-chloro-N-[6-(3-chloro-propionylamino)-9-oxo-4a,9,9a,10-tetrahydro-acridin-3-yl]-propionamide structure](https://image.chemsrc.com/caspic/120/351351-77-4.png)
Total 130, Current Page 1 of 13
1
2
3
4
5
| N-{9-[4'-(N,N-dimethylamino)phenylamino]}-3,6-bis(3-pyrrolidinopropionamido)acridine |
| UNII-Z7C5CD91WI |
| N,N'-(9-((4-(Dimethylamino)phenyl)amino)-3,6-acridinediyl)bis(1-pyrrolidinepropanamide) |
| BRACO-19 |
| 9-[4-(N,N-dimethylamino)phenylamino]-3,6-bis(3-pyrrolodinopropionamido) acridine |
| 1-Pyrrolidinepropanamide,N,N'-(9-((4-(dimethylamino)phenyl)amino)-3,6-acridinediyl)bis |